Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling

Launched by BEIJING TIANTAN HOSPITAL · Aug 22, 2014

Keywords

ClinConnect Summary

Participating Centers : 10 China high neurointervention volume (\>200) centers Rationale: Clopidogrel (75 mg/day), in combination with aspirin (100 mg/day), is currently the antiplatelet treatment of choice for prevention of stent thrombosis, and clinical trials have shown that, in high-risk patients, prolonged dual antiplatelet treatment is more effective than aspirin alone in preventing major thromboembolic events. However, despite the use of clopidogrel, a considerable number of patients continue to have thromboembolic events. Numerous in VITRO studies have shown that individual responsi...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients (≥18 years) in whom elective intracranial stent placement is scheduled after diagnostic angiography
• • Patients not treated by GPIIb/IIIa inhibitors prior to randomization.
• • Provided written consent for participation in the trial prior to any study-specific procedures or requirements
• Exclusion Criteria:
• • •Oral anticoagulation (Vitamin K Antagonists).
• • Contraindication for aspirin and/or clopidogrel or GPIIb/IIIa inhibitors or to increasing dose of clopidogrel or aspirin
• • Ongoing or recent bleeding and/or recent major surgery (\<3 weeks)
• • Severe liver dysfunction
• • Thrombocytopenia (Platelet count \<80000/µl).
• • IIb/IIIa inhibitors within a week prior to randomization
• • multiple intracranial aneurysms
• • Patient at risk of poor compliance to the study
• • Patient not affiliated to social security
• • Pregnant women, no signed inform consent
• • Any invasive or surgical planned intervention during the year after stent placement